Comparison of denosumab and zoledronic acid for the treatment of solid tumors and multiple myeloma with bone metastasis: a systematic review and meta-analysis based on randomized controlled trials
OncologiaSobre o estudo
- Desenho
- Metanálise
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- Journal of orthopaedic surgery and research
- Publicado em
- 22 jun 2021
- Citações
- 0
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Comparison of denosumab and zoledronic acid for the treatment of solid tumors and multiple myeloma with bone metastasis: a systematic review and meta-analysis based on randomized controlled trials
Lianghai Jiang, Xianghua Cui, Haoning Ma, Xiangsheng Tang
Descritores MeSH
- Bone Density Conservation Agents
- Zoledronic Acid
- Bone Neoplasms
- Multiple Myeloma
- Plasmacytoma
- Denosumab
- Humans
- Randomized Controlled Trials as Topic
- Treatment Outcome
Veja também
Estudos relacionados
- Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study
- Updated guidelines in the treatment of myeloma bone disease in 2025: consensus statement by the Medical and Scientific Advisory Group of Australia (MSAG) to Myeloma Australia
- Eficácia e segurança comparativas de biossimilares e originadores de denosumab na osteoporose pós-menopausa: uma meta-análise de ensaios controlados randomizados
- Efficacy and safety of denosumab in the treatment of prostate cancer with bone metastases: A systematic review and meta-analysis